Author: Ravaud Alain Dilhuydy Marie-Sarah
Publisher: Informa Healthcare
ISSN: 1471-2598
Source: Expert Opinion on Biological Therapy, Vol.5, Iss.6, 2005-06, pp. : 749-762
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
This paper is an overview on the place of IFN-α in metastatic renal cell carcinoma (MRCC). After a presentation of MRCC and the mode of action of IFN-α, the results of studies including IFN-α alone or in combination with IL-2, chemotherapy and other biological modifiers are presented. Finally, new trends for new drugs, including antiangiogenic therapies, are discussed.
Related content
Alpha Interferon for Treating Prostate Cancer
By Morales
Enzyme and Microbial Technology, Vol. 20, Iss. 3, 1997-02 ,pp. :
By Li Hui Li Xiangping Liu Qingyou Shi Zhendan Shi Deshun
Applied Biochemistry and Biotechnology, Vol. 171, Iss. 6, 2013-11 ,pp. :
Netrin-1 concentrations in patients with advanced gastric cancer and its relation with treatment
By Kefeli Umut Yildirim Mahmut Emre Aydin Dincer Madenci Ozlem Cakir Yasar Nurgul Sener Nur Mert Aslihan Guven Yuksel Sinemis Ercelep Ozlem Balvan Korkmaz Taner Yildiz Ramazan Gumus Mahmut
Biomarkers, Vol. 17, Iss. 7, 2012-11 ,pp. :